Evidence map›Paper›PMID 36324669›Full record

ArticleInfection and drug resistance2022

Tracking the Outbreak of Carbapenem-Resistant

Li Li, Renying Wang, Dan Qiao, Min Zhou, Peipei Jin

Abstract read
In one paragraph

Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Li LiDepartment of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, People's Republic of China.
Renying WangDepartment of Emergency, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, People's Republic of China.
Dan QiaoDepartment of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, People's Republic of China.
Min ZhouDepartment of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, People's Republic of China.
Peipei JinDepartment of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The spread of carbapenem-resistant Methods: Between Mar and Jun 2018, 10 CRKP isolates from 5 patients in the EICU ward of Shanghai Ruijin hospital north were collected. Modified carbapenem inactivation method (mCIM) and whole-genome sequencing (WGS) were performed on all 10 CRKP isolates. By integrating the genomic and epidemiological data of our isolates and 9 CRKP isolates from an outbreak in another hospital, a putative transmission map was constructed. Results: All 10 outbreak strains were carbapenemase positive in mCIM and belonged to the sequence type 11 (ST11) clone, harbored a set of resistance genes and virulence genes. The phylogenetic tree of CRKP isolates based on two outbreaks revealed that the initial isolate A1 in our EICU ward belonged to one branch of isolates in another hospital, this introductive isolate evolved and caused a subsequent outbreak in our EICU. Conclusion: Integration of genomic and epidemiological data can yield a clear transmission map of CRKP outbreak. Monitoring the rapid evolution of CRKP at the early stage of outbreak, CRKP monitoring after patients are discharged, active surveillance of newly admitted patients, environmental hygiene and efficient antibiotic treatment may be the key to prevent and control of CRKP outbreak.

Indexed as

carbapenem-resistant Klebsiella pneumoniaetransmission mapwhole-genome sequencing

Identifiers

PMID36324669
PMCPMC9621004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.